Trevi Q3 net loss $11.8M; cash $194.9M funds operations into 2028

Trevi Therapeutics, Inc.

2025-Q3 EPS reported -$0.26

Net loss of $11.8M for Q3 2025 vs. $13.2M in Q3 2024; R&D spend down to $10.1M.
Cash and marketable securities $194.9M at Sept 30, 2025; expected runway into 2028.
Preparing End-of-Phase 2 meeting request to FDA for IPF chronic cough in Q4 2025.
Phase 3 program for IPF chronic cough planned to start in H1 2026.
Phase 2b study for refractory chronic cough (RCC) also targeted for H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.